JP2020120660A5 - - Google Patents

Download PDF

Info

Publication number
JP2020120660A5
JP2020120660A5 JP2020051899A JP2020051899A JP2020120660A5 JP 2020120660 A5 JP2020120660 A5 JP 2020120660A5 JP 2020051899 A JP2020051899 A JP 2020051899A JP 2020051899 A JP2020051899 A JP 2020051899A JP 2020120660 A5 JP2020120660 A5 JP 2020120660A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020051899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020120660A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020120660A publication Critical patent/JP2020120660A/ja
Publication of JP2020120660A5 publication Critical patent/JP2020120660A5/ja
Pending legal-status Critical Current

Links

JP2020051899A 2017-03-27 2020-03-23 キメラ抗原受容体 Pending JP2020120660A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017061461 2017-03-27
JP2017061461 2017-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019509826A Division JP6761113B2 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体

Publications (2)

Publication Number Publication Date
JP2020120660A JP2020120660A (ja) 2020-08-13
JP2020120660A5 true JP2020120660A5 (enExample) 2021-05-13

Family

ID=63676179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019509826A Active JP6761113B2 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体
JP2020051899A Pending JP2020120660A (ja) 2017-03-27 2020-03-23 キメラ抗原受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019509826A Active JP6761113B2 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体

Country Status (16)

Country Link
US (2) US20210122831A1 (enExample)
EP (2) EP3604344A4 (enExample)
JP (2) JP6761113B2 (enExample)
KR (1) KR102333377B1 (enExample)
CN (2) CN110461881B (enExample)
AU (1) AU2018242408B2 (enExample)
BR (1) BR112019019941B1 (enExample)
CA (1) CA3057811A1 (enExample)
CL (1) CL2019002715A1 (enExample)
IL (1) IL269515B2 (enExample)
MX (1) MX2019011404A (enExample)
RU (1) RU2770002C2 (enExample)
SG (1) SG11201908659RA (enExample)
TW (1) TWI753141B (enExample)
WO (1) WO2018181207A1 (enExample)
ZA (1) ZA201906321B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
JP7684691B2 (ja) * 2019-02-25 2025-05-28 国立大学法人東京科学大学 キメラ抗原受容体
CN110669144B (zh) * 2019-10-12 2021-09-17 华夏源(上海)细胞基因工程股份有限公司 一种靶向b细胞成熟抗原的嵌合抗原受体及其应用
CN110684739B (zh) * 2019-11-11 2022-05-27 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其应用
CN112608902B (zh) * 2020-12-21 2024-07-02 广东昭泰细胞生物科技有限公司 一种第四代car-t细胞及其应用
WO2022251070A1 (en) * 2021-05-27 2022-12-01 Innovative Cellular Therapeutics Holdings, Ltd. Modified chimeric antigen receptor and use thereof
US20250332195A1 (en) 2021-07-16 2025-10-30 Noile-Immune Biotech Inc. Chimeric antigen receptor, cell expressing said receptor, pharmaceutical composition including said cell, method for producing said cell, and polynucleotide or vector including nucleotide sequence encoding said chimeric antigen receptor
US20250121002A1 (en) 2021-07-16 2025-04-17 Noile-Immune Biotech Inc. ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
WO2025096441A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Ganglioside gm2 as a target for cancer immunotherapy
WO2025096443A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors targeting monosialoganglioside gm2 and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2267131A1 (en) * 1996-10-04 1998-04-09 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with leukocyte adhesion inhibitor-1 (lai-1), and chemokine beta-11 (ck.beta.-11)
AU7449200A (en) * 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2004279736A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to ganglioside GM2
EP2107115A1 (en) * 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
IN2014CN02906A (enExample) * 2011-10-20 2015-07-03 Us Health
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN105025923B (zh) * 2012-12-06 2018-03-27 国立大学法人金泽大学 间皮瘤的治疗方法
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
SI3708579T1 (sl) * 2014-04-01 2024-09-30 Biontech Cell & Gene Therapies Gmbh Klavdin-6 specifični imunoreceptorji in T celični epitopi
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
EP3151854B1 (en) * 2014-06-06 2020-02-26 Memorial Sloan Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
EP3587446A1 (en) * 2014-09-19 2020-01-01 City of Hope Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
DK3597742T3 (da) * 2014-10-09 2022-10-03 Univ Yamaguchi Car-udtrykkende vektor og car-udtrykkende t-celler
KR20160056228A (ko) 2014-11-11 2016-05-19 주식회사 산내들 견과류의 껍질 분리 회수장치
WO2016161390A1 (en) * 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
RU2708160C2 (ru) * 2015-06-11 2019-12-04 Дженексин, Инк. Модифицированный белок интерлейкина-7 и способы его применения
EP3307282A4 (en) * 2015-06-12 2019-05-01 Immunomedics, Inc. DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS
US11612149B2 (en) * 2015-07-10 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Non-human animal having human CD3 gene substituted for endogenous CD3 gene
EP3344262A4 (en) * 2015-09-01 2019-03-20 Innate Tumor Immunity, Inc. IMMUNOCELLS WITH INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE THEREOF
AU2017235116B2 (en) * 2016-03-17 2019-11-07 Yamaguchi University Immunocompetent cell and expression vector expressing regulatory factors of immune function
AU2020406083A1 (en) * 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant

Similar Documents

Publication Publication Date Title
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2021185136A5 (enExample)
JP2021169491A5 (enExample)
JP2022068302A5 (enExample)
JP2021038271A5 (enExample)
JP2021028398A5 (enExample)
JP2024023385A5 (enExample)
JP2023116721A5 (enExample)
JP2021184963A5 (enExample)
JP2023022224A5 (enExample)
JP2020127428A5 (enExample)
JP2020042034A5 (enExample)
JP2024016014A5 (enExample)
JP2022523200A5 (enExample)
JP2021518389A5 (enExample)
JP2023100643A5 (enExample)
JP2022060295A5 (enExample)
JP2025506484A5 (enExample)
JP2020171301A5 (enExample)
JP2022537813A5 (enExample)
JP2021524864A5 (enExample)
JP2022022379A5 (enExample)
JP2023085551A5 (enExample)
JP2024534771A5 (enExample)